Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
CapsoVision, Inc. (CV)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$6.20-9.49%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CV yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Raise $14 million through private placement | It aims to raise $14 million to fund growth. | Intact | Failure to raise $14 million by mid-2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
CV is a small-cap healthcare growth story built around capsule endoscopy and AI features, with potential support from a favorable sector backdrop. Its long-term thesis is still developing: product milestones and customer expansion are progressing, but recent performance is below its industry cohort and risk has risen to high.
CV is valued at a premium to peers, with optionality, or potential from future product opportunities, driving the valuation gap. The evidence does not show a broad stack of expensive valuation, weak fundamentals, and turbulent conditions being priced in, so the premium appears difficult to justify on the current evidence.
Near term, consecutive earnings misses and a 53% estimated miss probability make the next report a key risk, while a guidance cut would be a meaningful negative. Over the multi-year view, progress on CapsoCam Colon, FDA clearance for AI Highlights, and rising product use and revenue support growth, though commercial execution remains mixed.
The thesis depends on continued progress toward CapsoCam Colon regulatory and clinical milestones, wider use of CapsoCam Plus, and successful commercialization of AI Highlights. Near term, weaker jobs data or another guidance cut could weigh on cyclical healthcare names, while continued earnings strength from sector bellwethers could support the sector backdrop.
Over the next 1 to 3 years, CV offers a product-led growth thesis with visible milestones, but high risk, recent earnings weakness, and a peer valuation premium leave meaningful execution questions. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company has a partnership with Canon for better sensors. |
| Intact |
| Partnership with Canon stalls or ends in 2026 |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Develop and launch CapsoCam Colon with AI module by Q3 2026 | CapsoVision is developing a new AI-assisted colon imaging product. | Improving | Failure to launch CapsoCam Colon with AI by Q3 2026 | Qualitative: AI clearance expected end Q3 2026; Colon submission targeted Q4 2026 News confirms AI clearance timeline for end Q3 2026 and Colon submission for Q4 2026, indicating a slight delay relative to the Q3 launch target. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “• Pipeline continues to advance with CapsoCam Colon™ on track for 510(k) submission in the fourth quarter of 2026, with ongoing enrollment in the CapsoCam UGI clinical study for pancreatic cancer detection.” “• Pipeline programs progressing as planned, including our second-generation of CapsoCam Colon with 510(k) submission expected in the third quarter of 2026, and initiation of a clinical study for CapsoCam UGI in pancreatic cancer detection with the first patient enrolled in May 2026.” Delivery assessment Nov 4, 2026 |
Revenue grows at least 36% in FY26 | A primary condition in CapsoVision, Inc.'s published investment case. The stated target is >=36% YoY revenue growth. | Intact | YoY revenue growth falls below 36% in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.42 → $-0.45 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-07-25 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-07-26 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-07-27 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-07-28 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-07-29 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-07-30 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-07-31 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-01 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-02 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-03 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-04 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-05 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-06 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-07 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-08 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-09 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-10 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-11 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-12 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-13 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-14 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-15 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-16 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-17 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-18 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-19 | $-0.42 | $21,475,000 | 1 / 1 |
| 2026-08-20 | $-0.43 | $19,745,000 | 1 / 1 |
| 2026-08-21 | $-0.43 | $19,745,000 | 1 / 1 |
| 2026-08-22 | $-0.43 | $19,745,000 | 1 / 1 |
| 2026-08-23 | $-0.43 | $19,745,000 | 1 / 1 |
| 2026-08-24 | $-0.43 | $19,745,000 | 1 / 1 |
| 2026-08-25 | $-0.43 | $19,745,000 | 1 / 1 |
| 2026-08-26 | $-0.43 | $19,745,000 | 1 / 1 |
| 2026-08-27 | $-0.43 | $19,745,000 | 1 / 1 |
| 2026-08-28 | $-0.43 | $19,745,000 | 1 / 1 |
| 2026-08-29 | $-0.44 | $19,822,500 | 1 / 1 |
| 2026-08-30 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-08-31 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-01 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-02 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-03 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-04 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-05 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-06 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-07 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-08 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-09 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-10 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-11 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-12 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-13 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-14 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-15 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-16 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-17 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-18 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-19 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-20 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-21 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-22 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-23 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-24 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-25 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-26 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-27 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-28 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-29 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-09-30 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-01 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-02 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-03 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-04 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-05 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-06 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-07 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-08 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-09 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-10 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-11 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-12 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-13 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-14 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-15 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-16 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-17 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-18 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-19 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-20 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-21 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-22 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-23 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-24 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-25 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-26 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-27 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-28 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-29 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-30 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-10-31 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-11-01 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-11-02 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-11-03 | $-0.45 | $19,281,667 | 1 / 1 |
| 2026-11-04 | $-0.45 | $19,281,667 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.